Clonal competition with alternating dominance in multiple myeloma

Jonathan J. Keats; Marta Chesi; Jan B. Egan; Victoria M. Garbitt; Stephen E. Palmer; Esteban Braggio; Scott Van Wier; Patrick R. Blackburn; Angela S. Baker; Angela Dispenzieri; Shaji Kumar; S. Vincent Rajkumar; John D. Carpten; Michael Barrett; Rafael Fonseca; A. Keith Stewart; P. Leif Bergsagel

doi:10.1182/blood-2012-01-405985

Clonal competition with alternating dominance in multiple myeloma

Jonathan J. Keats, Marta Chesi, Jan B. Egan, Victoria M. Garbitt, Stephen E. Palmer, Esteban Braggio, Scott Van Wier, Patrick R. Blackburn, Angela S. Baker, Angela Dispenzieri, Shaji Kumar, S. Vincent Rajkumar, John D. Carpten, Michael Barrett, Rafael Fonseca, A. Keith Stewart, P. Leif Bergsagel

Research output: Contribution to journal › Article › peer-review

448 Scopus citations

Abstract

Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

Original language	English (US)
Pages (from-to)	1067-1076
Number of pages	10
Journal	Blood
Volume	120
Issue number	5
DOIs	https://doi.org/10.1182/blood-2012-01-405985
State	Published - Aug 2 2012

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2012-01-405985

Cite this

Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Van Wier, S., Blackburn, P. R., Baker, A. S., Dispenzieri, A., Kumar, S., Rajkumar, S. V., Carpten, J. D., Barrett, M., Fonseca, R., Stewart, A. K., & Bergsagel, P. L. (2012). Clonal competition with alternating dominance in multiple myeloma. Blood, 120(5), 1067-1076. https://doi.org/10.1182/blood-2012-01-405985

Keats, JJ, Chesi, M, Egan, JB, Garbitt, VM, Palmer, SE, Braggio, E, Van Wier, S, Blackburn, PR, Baker, AS, Dispenzieri, A , Kumar, S , Rajkumar, SV, Carpten, JD, Barrett, M , Fonseca, R, Stewart, AK & Bergsagel, PL 2012, 'Clonal competition with alternating dominance in multiple myeloma', Blood, vol. 120, no. 5, pp. 1067-1076. https://doi.org/10.1182/blood-2012-01-405985

@article{40a8f280b6fa4a0cb9eb915f8081d9c6,

title = "Clonal competition with alternating dominance in multiple myeloma",

abstract = "Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.",

author = "Keats, {Jonathan J.} and Marta Chesi and Egan, {Jan B.} and Garbitt, {Victoria M.} and Palmer, {Stephen E.} and Esteban Braggio and {Van Wier}, Scott and Blackburn, {Patrick R.} and Baker, {Angela S.} and Angela Dispenzieri and Shaji Kumar and Rajkumar, {S. Vincent} and Carpten, {John D.} and Michael Barrett and Rafael Fonseca and Stewart, {A. Keith} and Bergsagel, {P. Leif}",

year = "2012",

month = aug,

day = "2",

doi = "10.1182/blood-2012-01-405985",

language = "English (US)",

volume = "120",

pages = "1067--1076",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Clonal competition with alternating dominance in multiple myeloma

AU - Keats, Jonathan J.

AU - Chesi, Marta

AU - Egan, Jan B.

AU - Garbitt, Victoria M.

AU - Palmer, Stephen E.

AU - Braggio, Esteban

AU - Van Wier, Scott

AU - Blackburn, Patrick R.

AU - Baker, Angela S.

AU - Dispenzieri, Angela

AU - Kumar, Shaji

AU - Rajkumar, S. Vincent

AU - Carpten, John D.

AU - Barrett, Michael

AU - Fonseca, Rafael

AU - Stewart, A. Keith

AU - Bergsagel, P. Leif

PY - 2012/8/2

Y1 - 2012/8/2

N2 - Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

AB - Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

UR - http://www.scopus.com/inward/record.url?scp=84861532638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861532638&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-405985

DO - 10.1182/blood-2012-01-405985

M3 - Article

C2 - 22498740

AN - SCOPUS:84861532638

SN - 0006-4971

VL - 120

SP - 1067

EP - 1076

JO - Blood

JF - Blood

IS - 5

ER -

Clonal competition with alternating dominance in multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this